BIT
GLMD icon

BlackRock Institutional Trust’s Galmed Pharmaceuticals GLMD Stock Holding History

BlackRock Institutional Trust’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-64
Closed -$88K – 3940
2015
Q4 		$88K Hold
64
– – ﹤0.01% 3764
2015
Q3 		$86K Hold
64
– – ﹤0.01% 3748
2015
Q2 		$117K Buy
64
+21
+49% +$36.5K ﹤0.01% 3704
2015
Q1 		$73K Hold
43
– – ﹤0.01% 3728
2014
Q4 		$45K Buy
43
+28
+187% +$30.4K ﹤0.01% 3779
2014
Q3 		$23K Buy
+15
New +$20.5K ﹤0.01% 3764

Other funds holding GLMD

6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
CA
CapWealth Advisors Franklin, Tennessee $1.35B AUM 34.16% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAD
Craig A. Drill $24.4M AUM 13.42% 1-Year Est. Return

BlackRock Institutional Trust's GLMD Position: Q1 2016 in Review

BlackRock Institutional Trust sold out of Galmed Pharmaceuticals (GLMD) in Q1 2016, closing a stake of 64 shares — an estimated $88K sold.

BlackRock Institutional Trust first reported a position in GLMD in Q3 2014 and held it in 6 quarters. The position peaked at $117K in Q2 2015. 18 funds tracked by Wall St. Rank hold GLMD as of Q1 2016.

  • BlackRock Institutional Trust reported no remaining Galmed Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • BlackRock Institutional Trust sold 64 Galmed Pharmaceuticals shares in Q1 2016, an estimated $88K.
  • BlackRock Institutional Trust first reported a position in Galmed Pharmaceuticals in Q3 2014 and held it in 6 quarters.
  • BlackRock Institutional Trust's Galmed Pharmaceuticals position peaked at $117K in Q2 2015.
  • 18 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2016.

Based on BlackRock Institutional Trust's 13F filing for Q1 2016, filed 10 May 2016.